Explore the intricate process of developing new cancer treatments in this informative video featuring Professor Paul Workman FRS FMedSci, Harrap Professor of Pharmacology and Therapeutics at ICR. Delve into the journey of drug discovery as Prof. Workman, former Chief Executive and President of ICR, shares his extensive experience leading the Centre for Cancer Drug Discovery. Learn about the groundbreaking research that resulted in 13 clinical candidates and the development of the AKT inhibitor capivasertib, currently under FDA Priority Review. Gain insights into the fundamental science, drug discovery techniques, and biomarker development that contributed to this significant achievement in cancer research. This 19-minute presentation is the first part of a two-part series, offering a comprehensive look at the challenges and breakthroughs in the field of cancer therapeutics.